GlassScriptPhysician profile
Amanda Massad
NPI 1467940825
$5,094.42
in general payments reported to CMS, 2019-2025
29 companies · $1,739 in 2025
The $1,739 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $119 · 2022: $1,053 · 2023: $1,264 · 2024: $920 · 2025: $1,739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,842 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,842.27 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,018.00 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $536.08 | 2022-2025 | |
| Lilly USA, LLC | $409.14 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $382.99 | 2022-2025 | Airsupra, Breztri, Andexxa |
| Amgen INC. | $376.08 | 2022-2025 | Evenity, Prolia, Prolia |
| Otsuka America Pharmaceutical, INC. | $374.19 | 2022-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $263.69 | 2022-2025 | Eliquis, Camzyos |
| Astellas Pharma US INC | $236.11 | 2023-2025 | Veozah |
| Exact Sciences Corporation | $225.79 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $209.96 | 2021-2025 | |
| Glaxosmithkline, LLC. | $171.58 | 2021-2025 | Arexvy, Shingrix |
| Mylan Specialty L.P. | $102.34 | 2022-2023 | Yupelri |
| Merck Sharp & Dohme LLC | $99.68 | 2021-2025 | Capvaxive, Gardasil 9, Lagevrio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.99 | 2022-2025 | Jardiance |
| Sumitomo Pharma America, INC. | $81.62 | 2023 | Gemtesa |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $65.34 | 2023 | |
| Janssen Pharmaceuticals, INC | $64.35 | 2022 | |
| Myriad Women'S Health, INC. | $56.65 | 2023 | Myrisk |
| Bayer Healthcare Pharmaceuticals INC. | $49.83 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $44.44 | 2022 | |
| Xeris Pharmaceuticals, INC. | $44.40 | 2023-2025 | Gvoke Hypopen |
| Globus Medical, INC. | $38.63 | 2025 | Senza |
| Stryker Corporation | $26.50 | 2025 | |
| Sunovion Pharmaceuticals INC. | $25.59 | 2022 | |
| Edwards Lifesciences Corporation | $23.85 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Viiv Healthcare Company | $21.92 | 2023 | Apretude |
| Kowa Pharmaceuticals America, INC. | $21.18 | 2025 | Zoryve |
| Gilead Sciences, INC. | $18.66 | 2023 | |
| Rgh Enterprises LLC | $15.84 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Massad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.